Idiopathic Pulmonary Fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis.
|
30698487 |
2020 |
Respiratory Distress Syndrome, Newborn
|
0.010 |
Biomarker
|
disease |
BEFREE |
Cut-off values of FLV ≤27.2 cm<sup>3</sup> and PARI ≥0.77 predicted the subsequent development of RDS.
|
28969484 |
2019 |
Tumor Progression
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Overexpression of PARPBP Correlates with Tumor Progression and Poor Prognosis in Hepatocellular Carcinoma.
|
30949905 |
2019 |
Liver carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Kaplan-Meier analyses suggested that upregulation of PARPBP was correlated with worse overall survival (OS) and recurrence-free survival (RFS) in HCC.
|
30949905 |
2019 |
Malignant neoplasm of stomach
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our results suggest that PARI plays potential oncogenic roles and functions as a transcriptional target and effector of FOXM1 in GC development.
|
29805304 |
2018 |
Orchitis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
These human aromatase-expressing transgenic mice (<i>AROM+</i>) develop testicular inflammation and impaired spermatogenesis during aging, and the present data show that this is associated with strikingly elevated <i>Nlrp3</i> expression in the testes compared to WT controls.
|
29907661 |
2018 |
Secondary malignant neoplasm of lung
|
0.010 |
Biomarker
|
disease |
BEFREE |
Knockdown of PARI by RNA inference decreased cell proliferation, migration, and invasion of GC cells <i>in vitro</i>, as well as reduced the xenograft tumor growth and lung metastasis formation <i>in vivo</i>.
|
29805304 |
2018 |
Stomach Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our results suggest that PARI plays potential oncogenic roles and functions as a transcriptional target and effector of FOXM1 in GC development.
|
29805304 |
2018 |
Male infertility
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Here, we utilized a transgenic mouse strain that overexpresses human CYP19, which encodes aromatase (AROM+ mice), and mice with knockout of Esr1, encoding estrogen receptor α (ERαKO mice), to analyze interactions between viable Leydig cells (LCs) and testicular macrophages that may lead to male infertility.
|
24762434 |
2014 |
Azoospermia, Nonobstructive
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, evaluation of molecular markers in the testes of patients with nonobstructive azoospermia (NOA) revealed enhanced expression of CYP19, GAS6, and AXL, which suggests that the AROM+ mouse model reflects human infertility.
|
24762434 |
2014 |
Pancreatic Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
In a mouse xenograft model of pancreatic cancer, PARI silencing was sufficient to reduce pancreatic tumor growth in vivo.
|
23436799 |
2013 |
Fanconi Anemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, we show that PARI knockdown suppresses the genomic instability of Fanconi Anemia/BRCA pathway-deficient cells.
|
22153967 |
2012 |
FANCONI ANEMIA, COMPLEMENTATION GROUP A (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, we show that PARI knockdown suppresses the genomic instability of Fanconi Anemia/BRCA pathway-deficient cells.
|
22153967 |
2012 |
Bladder neck obstruction
|
0.010 |
Biomarker
|
disease |
BEFREE |
Transgenic (Tg) male mice overexpressing aromatase (Cyp19a1) under the ubiquitin C promoter in the estrogen-susceptible C57Bl/6J genetic background (AROM+/6J) developed inguinal hernia by 2 months and severe BOO by 9 to 10 months, with 100% penetrance.
|
21356374 |
2011 |
Hernia, Inguinal
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Transgenic (Tg) male mice overexpressing aromatase (Cyp19a1) under the ubiquitin C promoter in the estrogen-susceptible C57Bl/6J genetic background (AROM+/6J) developed inguinal hernia by 2 months and severe BOO by 9 to 10 months, with 100% penetrance.
|
21356374 |
2011 |
Enzyme inhibition disorder
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
The enzyme inhibition and gene expression (RNA and protein) studies identified PLA2, LOX-5, LOX-12, COX-2, and perhaps AROM as likely sites of THF-diol regulation in MCF-7 cells.
|
18087590 |
2007 |
Gynecomastia
|
0.010 |
Biomarker
|
disease |
BEFREE |
AROM+ mice present several dysfunctions, such as adrenal and pituitary hyperplasia, cryptorchidism, Leydig cell hypertrophy and hyperplasia, and gynecomastia.
|
14982857 |
2004 |
Cryptorchidism
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
AROM(+) males present a multitude of severe structural and functional alterations in the reproductive organs, such as cryptorchidism associated with Leydig cell hyperplasia, dysmorphic seminiferous tubules, and disrupted spermatogenesis.
|
11356692 |
2001 |
Leydig cell hyperplasia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
AROM(+) males present a multitude of severe structural and functional alterations in the reproductive organs, such as cryptorchidism associated with Leydig cell hyperplasia, dysmorphic seminiferous tubules, and disrupted spermatogenesis.
|
11356692 |
2001 |
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
PARI, an element of the homologous recombination pathway of DNA repair<i>,</i>is involved in the regulation of cell cycle and carcinogenesis in pancreatic cancer.
|
29805304 |
2018 |
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
PARI overexpression promotes genomic instability and pancreatic tumorigenesis.
|
23436799 |
2013 |
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.020 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings offered a preclinical proof-of-concept for PARI as candidate therapeutic target to treat PDAC.
|
23436799 |
2013 |
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.020 |
Biomarker
|
disease |
BEFREE |
Depletion of C12orf48 sensitized PDAC cells to agents causing DNA damage and also enhanced DNA damage-induced G2/M arrest through reduction of PARP-1 enzymatic activities.
|
20931645 |
2011 |
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Using data from the Cancer Genome Atlas and Human Protein Atlas databases, PARPBP expression level and its clinical implication in HCC were identified by t test and Chi-square test.
|
30949905 |
2019 |
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Using data from the Cancer Genome Atlas and Human Protein Atlas databases, PARPBP expression level and its clinical implication in HCC were identified by t test and Chi-square test.
|
30949905 |
2019 |